One of the unexpected benefits of @OctantBio OA program is that the OAs keep coming back ❤️ @johnnyleebio was in our first class of OAs, built OCTOPUSv1, and is now a 3rd yr resident doing incredible things for patients. He’s even done some consulting work!
It's #MatchDay2025!! 👀 Check out these stars! 🤩 Thrilled to have matched with this talented bunch, looking forward to 2026/27! Welcome to the Trojan and LAG families! 🙌
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases.
I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known.
People can contact me directly at my first name (as written in my profile) at octant.bio.
Today we report Evo, a generalist foundation model for biology, on the cover of @ScienceMagazine. Trained on billions of DNA nucleotides, Evo was designed to capture two key aspects of biology: the multi-modality of the central dogma and the multi-scale nature of evolution.
A new Science study presents “Evo”—a machine learning model capable of decoding and designing DNA, RNA, and protein sequences, from molecular to genome scale, with unparalleled accuracy.
Evo’s ability to predict, generate, and engineer entire genomic sequences could change the way synthetic biology is done. Learn more in this week's issue: bit.ly/3OsmUPr
Excited to join @Ginkgo's Board of Directors. I've watched Ginkgo start out of MIT in 2008 and followed their journey closely over the years. I'm excited to work with @jrkelly@reshmapshetty and the rest of the team to make biology easier to engineer in the coming years.
We've started IND-enabling studies on a small molecule corrector for Rho-associated autosomal dominant retinitis pigmentosa (Rho-adRP). I thought it would be fun to spend some time walking through our approach and why we are excited. Long 🧵1/
Fantastic to be back @OctantBio. I’ve learned so much from this team since college, and I’m excited to be working on the clinical development of our corrector therapies. Check out what the Octonauts have been up to at octant.bio/pipeline
We're thrilled to welcome back @johnnyleebio, an original Octant Apprentice. Completing his medical degree at USC, he's now teaming up with us to push our rare disease programs to clinical development. For more details on our programs, see here! octant.bio/pipeline
What does synthetic biology, chemistry, robotics, and AI have in common?
They're all being used by @OctantBio to discover new drugs for previously untreatable diseases.
Episode 15 of S³ dives deep into the new and cutting edge world of drug discovery.
Would you like to screen thousands of protein interactions? Do you wish there were more orthogonal coiled coils?
Then we have a treat for you!
Freshly published in @NatureCommsnature.com/articles/s41467-0…
🧵1/N